The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.
McNamara CJ, et al. Among authors: claudio jo.
Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.
Blood Adv. 2018.
PMID: 30327374
Free PMC article.